

(Drint or Type Day

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL				
OMB Number: Estimated average burden hours per	3235-0104			
response	0.5			

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person = 667, L.P.		Date of Event Requiring Statement (Month/Day/Year) 07/19/2012			3. Issuer Name and Ticker or Trading Symbol XOMA Corp [XOMA]					
667 MADISON AVENUE 21	(First) ST FLOOR	(Middle)	-0//19/2012		(Che	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director		5. If Amendment, Date Original Filed(Month/Day/Year)		
NEW YORK, NY US 10065	(Street)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person		
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Beneficially Owned							
1.Title of Security (Instr. 4)			2. Amount of Securities B (Instr. 4)			es Beneficially Owned	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Nature of Indirect Beneficial Ownership nstr. 5)		
Common Stock					1,585,591 (1)		D			
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02) Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4)		2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Science (Month/Day/Year) 3. Title and Amount of Science (Instr. 4)			4. Conversion or Exercise Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
			Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 5)		
Common Stock Warrant (right	to buy)		<u>(2)</u>	<u>(3)</u>	Common Stock	792,796 (1) (4)	\$ 1.76	D		
D (1 0										

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
667, L.P. 667 MADISON AVENUE 21ST FLOOR NEW YORK, NY US 10065	X				

Signatures

667, L.P.; By: Baker Biotech Capital, L.P., its general partner, By: Baker Biotech Capital (GP), LLC, its general partner, Name: Julian C. Baker Title: Managing Member /s/ Julian C. Bake	
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The securities of Xoma Corporation reported herein are held directly by 667, L.P. ("667"), a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker and sole which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker and sole which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of the formation of the general partner of the general partner of the formation of the general partner of the general partner of the formation of the general partner of the general

- (2) Exercisable immediately.
- (3) Expiration date is five years from the date of Issuance.
- (4) Represents 1,585,591 warrant shares each of which is exercisable for .5 shares of the Issuer's common stock at an exercise price of \$1.76 per share.

Remarks:

Remarks:

Kelvin Neu, is a Managing Member of Baker Bros. Advisors LLC and is a director of Xoma Corporation. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, 667, L.P. is deemed a director by deputization by

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.